MARKET

LLY

LLY

Lilly
NYSE

Real-time Quotes | Nasdaq Last Sale

206.92
+6.38
+3.18%
After Hours: 207.60 +0.68 +0.33% 19:59 03/05 EST
OPEN
201.02
PREV CLOSE
200.54
HIGH
207.67
LOW
200.88
VOLUME
3.88M
TURNOVER
--
52 WEEK HIGH
218.00
52 WEEK LOW
117.06
MARKET CAP
198.32B
P/E (TTM)
30.48
1D
5D
1M
3M
1Y
5Y
Global Injectable Drug Delivery System Market 2021 - Industry Analysis by Size, Share, Trends and Forecast to 2026
Mar 06, 2021 (The Expresswire) -- The global Injectable Drug Delivery System market research report comprises of the comprehensive overview of all the...
The Express Wire · 20h ago
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. rallied 3.18% to $206.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...
marketwatch.com · 1d ago
DJ AbCellera's Covid-19 Treatment Gets Recommendation From European Regulators
Dow Jones · 1d ago
AbCellera's bamlanivimab wins EMA's positive recommendation
AbCellera ([[ABCL]] -6.1%) announced that the European Medicines Agency's ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive recommendation for bamlanivimab alone and in combination with etesevimab
Seekingalpha · 1d ago
BRIEF-EMA Issues Advice on Lilly's COVID-19 Antibody Combination
reuters.com · 1d ago
EMA's Medicinal Committee Backs Eli Lilly's COVID-19 Antibody Therapy
Benzinga · 1d ago
Eli Lilly’s antibody combo wins positive opinion in Europe against COVID-19
Eli Lilly and Company ([[LLY]] +2.0%) announced that the European Medicines Agency has issued a positive opinion for its bamlanivimab alone and bamlanivimab/ etesevimab combination for the treatment of confirmed COVID-19.The decision
Seekingalpha · 1d ago
DJ Eli Lilly Gets CHMP Positive Opinion for Covid-19 Treatments >LLY
Dow Jones · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LLY. Analyze the recent business situations of Lilly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LLY stock price target is 216.14 with a high estimate of 256.00 and a low estimate of 170.00.
EPS
Institutional Holdings
Institutions: 2.41K
Institutional Holdings: 822.06M
% Owned: 85.77%
Shares Outstanding: 958.43M
TypeInstitutionsShares
Increased
637
87.38M
New
312
1.30M
Decreased
665
37.99M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Ricks
Chief Financial Officer/Senior Vice President
Anat Ashkenazi
Senior Vice President/Chief Information Officer
Aarti Shah
Senior Vice President/Chief Scientific Officer
Daniel Skovronsky
Senior Vice President/Chief Compliance Officer
Melissa Barnes
Senior Vice President/General Counsel
Anat Hakim
Senior Vice President/Director of Human Resources
Stephen Fry
Senior Vice President
Patrik Jonsson
Senior Vice President
Michael Mason
Senior Vice President
Johna Norton
Senior Vice President
Myles O'Neill
Senior Vice President
Leigh Pusey
Senior Vice President
Anne White
Senior Vice President
Ilya Yuffa
Senior Vice President
Alfonso Zulueta
Independent Director
Ralph Alvarez
Lead Director/Independent Director
Juan Luciano
Director
Gabrielle Sulzberger
Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn Bertozzi
Independent Director
Michael Eskew
Independent Director
J. Erik Fyrwald
Independent Director
Jamere Jackson
Independent Director
Kimberly Johnson
Independent Director
William Kaelin
Independent Director
Marschall Runge
Independent Director
Kathi Seifert
Independent Director
Jackson Tai
Independent Director
Karen Walker
Declaration Date
Dividend Per Share
Ex-Div Date
12/14/2020
Dividend USD 0.85
02/11/2021
10/19/2020
Dividend USD 0.74
11/12/2020
07/15/2020
Dividend USD 0.74
08/13/2020
05/04/2020
Dividend USD 0.74
05/14/2020
12/16/2019
Dividend USD 0.74
02/13/2020
10/21/2019
Dividend USD 0.645
11/14/2019
06/19/2019
Dividend USD 0.645
08/14/2019
05/06/2019
Dividend USD 0.645
05/16/2019
12/19/2018
Dividend USD 0.645
02/14/2019
10/15/2018
Dividend USD 0.563
11/14/2018
06/18/2018
Dividend USD 0.563
08/14/2018
05/07/2018
Dividend USD 0.563
05/16/2018
12/11/2017
Dividend USD 0.563
02/14/2018
10/16/2017
Dividend USD 0.52
11/14/2017
06/19/2017
Dividend USD 0.52
08/11/2017
05/01/2017
Dividend USD 0.52
05/11/2017
12/13/2016
Dividend USD 0.52
02/13/2017
10/18/2016
Dividend USD 0.51
11/10/2016
06/20/2016
Dividend USD 0.51
08/11/2016
05/02/2016
Dividend USD 0.51
05/11/2016
12/08/2015
Dividend USD 0.51
02/10/2016
10/19/2015
Dividend USD 0.5
11/10/2015
06/15/2015
Dividend USD 0.5
08/12/2015
05/04/2015
Dividend USD 0.5
05/14/2015
12/15/2014
Dividend USD 0.5
02/11/2015
10/20/2014
Dividend USD 0.49
11/12/2014
06/16/2014
Dividend USD 0.49
08/13/2014
05/05/2014
Dividend USD 0.49
05/13/2014
12/16/2013
Dividend USD 0.49
02/12/2014
10/21/2013
Dividend USD 0.49
11/13/2013
06/18/2013
Dividend USD 0.49
08/13/2013
  • All
  • Financials
  • Insiders
More
About LLY
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Webull offers kinds of Eli Lilly And Co stock information, including NYSE:LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.